Live
FierceBiotechCancer-focused Parabilis’ upsized $670M IPO breaks new for record for biotechsFierceBiotechSanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continueLabiotechBeyond amyloid and dopamine: emerging technologies reshaping neurologyEndpoints NewsParabilis' $670M IPO sets new biotech record, will fund cancer drugClinical OMICsExposure to Moderate Air Pollution Raises Cardiovascular Disease RiskEndpoints NewsEli Lilly's claims data deadline may kick off new 340B fightClinical OMICsFirst Phase III for Resected CRC ctDNA-Guided Therapy Shows Mixed ResultsAgilentAgilent Showcases Integrated Mass Spectrometry and Chromatography Solutions at ASMS 2026 - the-scientist.comEndpoints NewsGrace Science says FDA bottleneck jeopardizes rare disease therapyClinical OMICsDigital Pathology and the NHS: Overcoming Barriers to a More Connected FutureFierceBiotechFueled by M&A and partnerships, biotech is poised for continued growth: EYFierceBiotechGalmed acquires Colospan in $4.5M deal as it eyes $6B GI dx market
Gilson 18 avr. 2026

Earl Gilson - The Press Democrat

Earl Gilson - The Press Democrat

Original
Contenu indisponible. Consultez la source originale.